Warner Bros. Discovery hikes prices for Max streaming service

Warner Bros. Discovery hikes prices for Max streaming service


In this photo illustration, the Warner Bros. Discovery logo is displayed on a smartphone screen.

Rafael Henrique | Sopa Images | Lightrocket | Getty Images

Warner Bros. Discovery‘s Max announced price increases for its ad-free options on Tuesday, as a range of streamers make their memberships more expensive. 

The move comes only 12 days before the debut of season two of HBO’s “Game of Thrones” prequel “House of the Dragon,” whose series premiere garnered nearly 10 million viewers, making it the biggest in HBO’s history.  

Max currently has three pricing options: with ads; ad-free; and ultimate ad-free, which allows for more devices and downloads than the cheaper plans.

The price of the ad-free option of the streaming service will increase by $1 per month to $16.99, while the yearly ad-free plan will rise by $20 a year to $169.99. The cost of the ultimate ad-free plan will also increase by $1 per month to $20.99, while the yearly ultimate plan will jump $10 per year to $209.99. The ad-supported option will remain unchanged at $9.99 a month or $99.99 a year.

While the prices will take effect immediately for new subscribers, existing subscribers will see the price hike starting from their next billing cycle on or after July 4.

The price hike follows Warner Bros. Discovery and Disney’s decision to bundle their streaming services, Disney+, Max and Hulu. The bundle will be available in both ad-supported and ad-free tiers. While the pricing has not been disclosed, CNBC reported that it will be offered at a discount in an effort to make it a more desirable option.

Warner Bros. Discovery last month missed both top- and bottom-line estimates for its first-quarter earnings report, despite adding two million direct-to-consumer streaming subscribers during the quarter. 

In the company’s earnings call, CEO David Zaslav said Warner Bros. Discovery is hoping the subscribers will stick with the bundle offering to take advantage of cheaper prices, decreasing the loss of customers, which he said has been “the killer” in the streaming business.

This is only the second time Max has raised prices for its ad-free service since its launch. In early 2023, Max raised the ad-free tier price from $14.99 to $15.99 a month, an increase the company said would allow it to invest in its content and user experience. 

Prices are rising across the streaming world. Last month, Comcast’s NBCUniversal hiked both the ad-supported and ad-free offerings of its Peacock platform by $2 per month ahead of its Olympics coverage later this summer. Last summer, Netflix got rid of its cheapest basic ad-free option in the U.S. and U.K. markets, offering a cheaper yet ad-supported option and more expensive ad-free options instead.

Disclosure: Comcast is the parent company of NBCUniversal and CNBC.

Don’t miss these exclusives from CNBC PRO



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More